Actinobacillus pleuropneumoniae (App) is the etiological agent of porcine pleuropneumonia. The virulence of the fifteen serotypes of App is mainly determined by the three major RTX toxins ApxI, ApxII and ApxIII, which are secreted by the different serotypes in various combinations. A fourth RTX toxin, ApxIV, is produced by all 15 serotypes specifically during infection of pigs, but not under in vitro conditions. Pigs infected with App show specific antibodies directed against ApxIV. The analysis of sera of experimentally infected pigs revealed that ApxIV-immunoblots detected App infections in the second to third week post infection. We developed an indirect ELISA based on purified recombinant N'-terminal moiety of ApxIV that showed a specificity of 100% and a sensitivity of 93.8%. The prevalidation study of the ApxIV-ELISA revealed that the latter was able to detect App-positive herds, even if clinical and pathological signs of porcine pleuropneumonia were not evident.
Introduction: Surveillance of App infections can be done by serological examination of pig herds. For a few selected serotypes such as serotype 2 and the group of serotypes 1-9-11, ELISA kits are currently available on the market. Recently other serotypes such as serotype 7 and/or 12 are emerging in Switzerland and were also detected in other parts of Europe. For such serotypes, there are no commercial ELISA tests available. Apx toxins are highly immunogenic and thus induce a strong production of antibodies in animals infected with App. However, ApxI, ApxII and ApxIII are also secreted by other Actinobacillus species like A. rossii, A. suis, and the recently discovered, non-pathogenic "Actinobacillus porcitonsillarum" which can induce antibodies against these toxins in pigs, whereas ApxIV is specific to the species of App (Schaller et al., 2001) . The present study aims to assess the seroconversion against ApxIV in swine with porcine pleuropneumonia using immunoblot analysis and to develop and pre-validate an ApxIV-based indirect ELISA for App.
Materials and Methods:
Recombinant N`ApxIV was used on immunoblots (IB) to serologically detect antibodies against ApxIV in App infected pigs. Subsequently an indirect ELISA based on N`ApxIV was developed. Cut off level, sensitivity and specificity were determined by testing positive sera of experimentally infected pigs, pig herds naturally infected by App and negative sera of specific pathogen free (SPF) and App-free herds. These sera were tested by N`ApxIV-IB and by LPS ELISA. Furthermore, the lungs and tonsils of the animals, from which the sera originated were tested by PCR and/or by isolation of App. App-positive and negative field sera were tested by N`ApxIV-IB and ELISA. Seroconversion against ApxI, ApxII and ApxIII was examined, by testing sera of App-positive and negative herds by IB.
Results:
A significantly higher number of animals showed reactions towards ApxI, ApxII and ApxIII than towards ApxIV. In particular sera from herds that were free of porcine pleuropneumoniae showed immunological reactions to one or several of ApxI, ApxII or ApxIII but not ApxIV. Pigs with known history of App infections constantly showed anti ApxIV antibodies. The progress of the immune response to ApxIV investigated by analysis of sera from pigs experimentally infected with App serotype 9 showed seroconversion to ApxIV between 20-28 days p.i., as indicated by immunoblot analysis and measured by ApxIV-ELISA with continued increase. In order to pre-validate an ApxIV-ELISA, field sera of pigs PD 04 263 POSTER PRESENTATIONs POSTER PRESENTATIONs originating from different herds with problems of porcine pleuropneumonia and/or confirmed App infections, as determined by isolation of App or serological diagnosis using currently available tests, were analysed by ApxIV-ELISA. In addition, sera from slaughterhouse pigs with typical lung lesions were scored by the ApxIV-ELISA. Thereof, 45 sera (52 %) were positive. Among the 86 slaughterhouse sera, 35 samples originated from pigs of which App was isolated from lungs. Among these 35 sera, 16 samples (46%) tested were positive in the ApxIV-ELISA, 15 (43%) were negative, and 4 (11%) showed ELISA titers close to the cut-off value. Out of the remaining 51 slaughterhouse sera of pigs, from which App was not isolated by standard procedures, 29 (57%) gave positive results, 20 (39%) gave negative results, and 2 (4%) were close to the cut-off value. In the negative sampling of sera used for the prevalidation, totally 52 sera from 40 pigs and 12 sows from herds known to be free of App infections showed to be negative in the ApxIV-ELISA.
Discussion: This study shows that immunoblot and indirect ELISA detect antibodies against ApxIV in App infected pigs 20 days post infection. It reveals that the ApxIV ELISA is a highly specific and sensitive test to detect seroconversion against ApxIV in pig herds infected by App. The specificity of the ApxIV-ELISA was shown to be very high since no sera from pigs and sows from App-free herds gave ELISA titers above the cut-off value. Furthermore it must be noted that sera from pigs experimentally infected with the non-pathogenic Actinobacillus species "A. porcitonsillarum", were negative in the ApxIV-ELISA although this new bacterium caused sero-conversion to LPS capsular antigens of App, a fact that severely hampered serotype-specific ELISA under certain conditions (Gottschalk et al., 2003) . It further supports other studies in the observation that ApxI, ApxII and ApxIII are not specific enough for sero diagnostic use. The relatively high number of serological reactions to ApxII and ApxIII in pigs that were free of App is presumably due to other Actinobacillus species such as A. suis and A. rossii, and the recently discovered "Actinobacillus porcitonsillarum" (Schaller et al., 2000; Frey and Kuhnert 2002; Gottschalk et al., 2003) . We conclude from the present study that the ApxIV-ELISA is a highly sensitive and specific serological test for the diagnosis of infections of pigs and pig herds with any of the serotypes of App. Thus, this test is promising for reliable surveillance and control of App infection.
